InVivo Therapeutics Hldgs Corp (fka NVIVQ)

[skeetly]

Tweet convo where Zacks analyst proves Biotech Sage HUD pricing model is in error

(FROM YAHOO BOARD)

Here is the Teewhitter conversation wherein the Zacks analyst Jason Napodano proved Biotech Sage's pricing assumptions for the HUD device biopolymer scaffold was grossly wrong in its assumptions:

06-27-2013: Jason Napodano: "The HDE trial will start (eventually) and succeed b/c of the low hurdle for success. That's my call."

Biotech Sage: "The product will have no pricing power based on the HDE Trial. Reynolds asserts orphan pricing and does not blink for a second."

Jason Napodano: "Not true. HDE does not limit pricing power or profits. You need to read the new law put into place earlier this year."

Jason Napodano: "I spoke to the FDA-ORDP for about 60 min before I wrote this article to make sure I got the facts:"